Drug Trial Radar · NCT00415805
Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent
Last checked: Nov 20, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Dec 2006
Primary completion
Dec 2008
Study completion Feb 2009
Sponsor
- Lead sponsor
- Bracco Diagnostics, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 25, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an explorative small pilot study comparing two MRA contrast agents, one of which has been on the market for a few years and the other fairly new to the market. Since the study is explorative and designed to provide preliminary information for consideration for a future larger study, sample size is not based on statistical assumptions.
Conditions
- Steno-occlusive Disease
Interventions
MultihanceDrug
0.5 Molar, single injection at 0.2 mL/kg
vasovistDrug
0.25 molar single injection 0.03 ml/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and specificity compared to DSATime frame: post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bracco Imaging, S.p.A
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.